Trial Profile
A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemarthrosis; Haemophilic arthropathy
- Focus Therapeutic Use
- 02 Jul 2021 Status changed from recruiting to discontinued.
- 27 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 22 Feb 2019 Planned End Date changed from 1 Jun 2016 to 31 Dec 2020.